Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals

被引：0
|
作者：
Kazuto Tajiri
Kazuhiko Okada
Hiroyuki Ito
Kengo Kawai
Yoshiro Kashii
Yoshiharu Tokimitsu
Nozomu Muraishi
Aiko Murayama
Yuka Hayashi
Masami Minemura
Terumi Takahara
Yukihiro Shimizu
Ichiro Yasuda
机构：
[1] University of Toyama,Third Department of Internal Medicine, Faculty of Medicine
[2] Gastroenterology,undefined
[3] Toyama Red Cross Hospital,undefined
[4] Gastroenterology,undefined
[5] Takaoka Municipal Hospital,undefined
[6] Gastroenterology,undefined
[7] Nanto Municipal Hospital,undefined
[8] Gastroenterology,undefined
[9] Saiseikai Toyama Hospital,undefined
来源：
BMC Gastroenterology | / 23卷
关键词：
Hepatitis C virus; Thrombocytopenia; Hypersplenism; Direct-acting antiviral;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals
    Pietsch, V.
    Deterding, K.
    Attia, D.
    Ringe, K.
    Cornberg, M.
    Gebel, M.
    Manns, M. P.
    Wedemeyer, H.
    Potthoff, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S532 - S533
  • [42] The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study
    Toyoda, Hidenori
    Kumada, Takashi
    Tada, Toshifumi
    Mizuno, Kazuyuki
    Sone, Yasuhiro
    Akita, Tomoyuki
    Tanaka, Junko
    Johnson, Philip J.
    LIVER INTERNATIONAL, 2019, 39 (03) : 448 - 454
  • [43] Resistance to Direct-Acting Antivirals
    Jean-Michel Pawlotsky
    Current Hepatitis Reports, 2012, 11 (3) : 188 - 194
  • [44] Human genetics of HCV infection phenotypes in the era of direct-acting antivirals
    Pierre Nahon
    Aurélie Cobat
    Human Genetics, 2020, 139 : 855 - 863
  • [45] Management of acute HCV in the era of direct-acting antivirals: implications for elimination
    Martinello, Marianne
    Matthews, Gail V.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (04): : 256 - 257
  • [46] Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021
    Martinez, Anthony
    Khan, Tipu
    Dylla, Doug
    Marcinak, John
    Collins, Michelle
    Saget, Brad
    Conway, Brian
    JOURNAL OF HEPATOLOGY, 2022, 77 : S596 - S596
  • [47] Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals
    Cavero, M.
    Marino, Z.
    Navines, R.
    Pariente, J.
    Munoz Moreno, E.
    Bartres, C.
    Nacar, L.
    Lens, S.
    Rodriguez-Tajes, S.
    Canizares, S.
    Bargallo, N.
    Forns, X.
    Martin-Santos, R.
    EUROPEAN PSYCHIATRY, 2021, 64 : S254 - S254
  • [48] HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
    Rice, Donald P., Jr.
    Faragon, John J.
    Banks, Sarah
    Chirch, Lisa M.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2016, 4 (03) : 234 - 240
  • [49] The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?
    Vachon, Marie-Louise
    Dieterich, Douglas T.
    SEMINARS IN LIVER DISEASE, 2011, 31 (04) : 399 - 409
  • [50] Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
    Feld, Jordan J.
    CURRENT DRUG TARGETS, 2017, 18 (07) : 851 - 862
12345